Nexentis Subsidiary MitoCareX Bio Optimizes Hit Molecule, Reaching Key Drug Discovery Milestone
NXTS sits 35% above its 52-week low of $3.38.
Summary
Nexentis Technologies Inc. announced that its wholly-owned subsidiary, MitoCareX Bio Ltd., has successfully optimized a hit molecule, marking its first drug discovery milestone since acquisition. This optimized molecule demonstrates substantially improved pharmaceutical properties and is considered a pivotal inflection point for MitoCareX's program, which targets mitochondrial SLC25 carrier proteins for hard-to-treat cancers and inflammatory metabolic diseases. This positive pipeline development is particularly significant for Nexentis, a micro-cap company that recently disclosed a 'going concern' warning and substantial accumulated deficit in its latest 10-K and S-3 filings. The company is now advancing towards generating a lead molecule and initiating pre-clinical trials, which will be key next steps for investors to monitor.
At the time of this announcement, NXTS was trading at $4.57 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $3.4M. The 52-week trading range was $3.38 to $109.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.